Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy
using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with
reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling
time lower than 5 years)